Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Rivera

Nurse Practitioner Palm Bay, FL Nurse Practitioner

NPI 1356585624 CMS profile 10943523

1761 Palm Bay Rd Ne, Palm Bay, FL 32905

Open in the dashboard

General payments

$5,937

241 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Rivera of Palm Bay, FL is reported in the CMS Open Payments database as having received $5,937 across 241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $291 6
2024 General $265 9
2023 General $1,502 66
2022 General $2,592 80
2021 General $1,287 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Rivera
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Jennifer Rivera were reported at $291. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Jennifer Rivera Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,287 $135 $40–$426 $132
2022 $2,592 $152 $48–$470 $149
2023 $1,502 $166 $54–$529 $160
2024 $265 $173 $55–$556 $164
2025 $291 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merz North America, Inc. $2,192 19 payments
  2. Janssen Biotech, Inc. $1,412 95 payments
  3. AbbVie, Inc. $760 49 payments
  4. Allergan Inc. $226 10 payments
  5. Sun Pharmaceutical Industries Inc. $213 13 payments
  6. Ortho Dermatologics, a division of Bausch Health US, LLC $152 9 payments
  7. Lilly USA, LLC $141 6 payments
  8. Genzyme Corporation $124 5 payments
  9. LEO Pharma Inc. $88 4 payments
  10. Novartis Pharmaceuticals Corporation $84 4 payments
  11. Other $546 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,657 238 payments
  2. Education $280 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,185 70 payments
  2. Xeomin $545 6 payments
  3. SKYRIZI $271 22 payments
  4. STELARA $226 25 payments
  5. BOTOX $171 7 payments
  6. SIMPONI ARIA $169 21 payments
  7. REMICADE $169 21 payments
  8. SIMPONI $169 21 payments
  9. DUOBRII $152 9 payments
  10. JUBLIA $152 9 payments
  11. Other $1,533 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

140

Median for Nurse Practitioner: 389

Drug cost

$3,607

Median for Nurse Practitioner: $21,885

Branded share of claims

8.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 14 $904
Fluorouracil Generic 13 $844
Doxycycline Hyclate Generic 17 $546
Triamcinolone Acetonide Generic 32 $512
Ketoconazole Generic 20 $354
Ssd Silver Sulfadiazine Brand 12 $256
Hydrocortisone Generic 19 $130
Hydroxyzine Hcl Generic 13 $60

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$30,034

Medicare's payments for the services billed

Medicare patients

174

Average age 75

Services billed

628

87 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 26%
Ischemic heart disease 26%
Chronic kidney disease 26%
Atrial fibrillation 18%
COPD 18%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $166
$166 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $38
$38 — —
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record